Warren Buffet aims to hold stocks forever. Were a bit less patient. But we like playing the long game: picking a few solid companies, sticking with them through tough times and hanging on for years, even a decade or more. Investing for the long haul can smooth out the risks of buying individual stocks, which may tumble or stay depressed for ages before taking off. A companys innovations may also take years to bear fruit. Moreover, businesses with attractive growth often trade at lofty prices that may not be sustainable. The longer you stick with a stock that has stumbled, however, the greater....More>>>
Late last year, Japan legalized casinos in the country, opening up a gaming industry that could generate as much as $30 billion a year in revenues and become the second-largest casino market in the world. As several players scout for licenses, Las Vegas Sands (NYSE: LVS) is ready to invest heavily in the region, committing to an initial investment of $10 billion. While this is a significant number, if Las Vegas Sands is able to capture a decent share in the market, it would make sense given the revenue potential of the market. Currently, Macau and Singapore are the largest value drivers of the....More>>>
Family and friends lend out about $89 billion in cash each year. More than a third of that total is used to help finance a new business while 6% of first-time home buyers get help from (usually) their parents. About a quarter of those loans were never paid back at all and more than 40% were only paid back partially.
The moral here is not to lend more than you can afford to lose. Sort of like playing poker or blackjack in a casino.
But what about lending your credit card to someone else, either a family member or good friend? How likely is that result in a bad outcome? According....More>>>
By Scott Tzu with Parke Shall
When a company is in a distressed situation, a lot of times it’s not going to come out and tell the public that it is looking at a reorganization or considering filing bankruptcy. As investors, we are often left to draw our own conclusions based on piecemeal that we can obtain regarding the company in question. We believe the signs and signals continue to indicate to us that Concordia Healthcare (NASDAQ:CXRX) is not a stock to be in, has limited turnaround prospects, and could very well be heading for restructuring.
By now, most readers will....More>>>
Research Coverage- Viking Therapeutics (VKTX)
This is meant as a scientific/business development post as to the merits of VKTX. It is well known VKTX is undervalued (by upwards of 40x), but these details will not be discussed here. For a more detailed valuation analysis, see the end of Zacks SCR’s post.
Viking Therapeutics is a clinical stage biopharmaceutical company specializing in metabolic and endocrine disorders. They currently have two clinical assets: VK5211, a selective androgen receptor modulator (SARM) for hip fracture; and VK2809 a thyroid receptor....More>>>